Hexima Limited ACN 079 319 314 (Company) wishes to advise shareholders that it is extending the invitation for shareholders to participate in the rights issue of 6 new shares for every 10 shares which shareholders held on the relevant record date (Offer), under the...
Hexima Interim Financial Report 31 Dec 16
Hexima is pleased to offer each existing shareholder the opportunity to participate in a fully underwritten non-renounceable pro-rata offer to subscribe for 6 New Shares for every 10 Shares held on the Record Date to raise a maximum amount of $3,896,663 (before costs...
Presentations and Results from the 2016 Hexima Limited Annual General Meeting
NOTICE IS GIVEN that the Annual General Meeting of the ordinary shareholders of Hexima Limited
Click here to view the October 2016 shareholder update presentation.
Hexima’s Annual Financial Report for the year ended 30 June 2016
Shares in Hexima Limited are not traded on the ASX. The last off-market transfer of shares registered by the Company, as at the close of business on 30 June 2016, was at the price of $0.20 per share.
Hexima’s Chief Science Officer, Professor Marilyn Anderson, Onychomycosis Project Leader, Dr Michael Baker and Researcher, Dr Brigitte Hayes, have presented Hexima’s human antifungal technology at ASM Microbe 2016. The conference is an opportunity to showcase the benefits of Hexima’s technology and our progress towards clinical trials for fungal nail infections (onychomycosis). PhD Student Kathy Parisi also presented work relating to Hexima’s antifungal technology.